TECHNOLOGICAL WATCH SERVICE
Technical Standard
Powered by:

F2315 Standard Guide for Immobilization or Encapsulation of Living Cells or Tissue in Alginate Gels has been revised to F2315-18

Significance and Use

4.1 The main use is to immobilize, support, or suspend living cells or tissue in a matrix. The use of an encapsulation/immobilization system may protect cells or tissues from immune rejection. When immobilizing biological material in alginate gels, there are numerous parameters that must be controlled. This guide contains a list of these parameters and describes the methods and types of testing necessary to properly characterize, assess, and ensure consistency in the performance of an encapsulation system using alginate. This guide only covers single gelled beads, coated or not, and not double capsules or other constructs.

4.2 The alginate gelation technology covered by this guide may allow the formulation of cells and tissues into biomedical devices for use as tissue engineered medical products or drug delivery devices. These products may be appropriate for implantation based on supporting biocompatibility and physical test data. Recommendations in this guide should not be interpreted as a guarantee of clinical success in any tissue engineered medical product or drug delivery application.

1. Scope

1.1 This guide discusses information relevant to the immobilization or encapsulation of living cells or tissue in alginate gels. Immobilized or encapsulated cells are suitable for use in biomedical and pharmaceutical applications, or both, including, but not limited to, Tissue Engineered Medical Products (TEMPs).

1.2 This guide addresses key parameters relevant for successful immobilization and encapsulation in alginate gels.

1.3 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.4 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.5 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.


2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard./p>

USP Document

USP Monograph USP 40/NF35

ASTM Standards

F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices

F1903 Practice for Testing for Cellular Responses to Particles in vitro

F1904 Practice for Testing the Biological Responses to Particles in vivo

F1905 Practice For Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity

F1906 Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte Proliferation, and Cell Migration

F2064 Guide for Characterization and Testing of Alginates as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications

F2312Terminology Relating to Tissue Engineered Medical Products

Other Referenced Documents

21 CFR Part 312 Code of Federal Regulations Title 21, Part 312 Investigational New Drug Application Available from U.S. Government Printing Office, Superintendent of Documents, 732 N. Capitol St., NW, Washington, DC 20401-0001, http://www.access.gpo.gov.

International Conference on Harmonization (ICH) S2 A Standard Battery for Genotoxicity Testing of Pharmaceuticals (July 1997) Available from https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074929.pdf or http://www.ich.org/products/guidelines/safety/safety-single/article/guidance-on-genotoxicity-testing-and-data-interpretation-for-pharmaceuticals-intended-for-human-use.html

ISO 10993 Biological Evaluation of Medical DevicesPart 1: Evaluation and Testing Within a Risk Management Process Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, http://www.ansi.org.

» Code: ASTM F2315 - 18

» Committee: Subcommittee: F04.43

» More Information

« Go to Technological Watch



AIMPLAS - Instituto Tecnológico del Plástico | C/ Gustave Eiffel, 4 (Valčncia Parc Tecnolňgic) | 46980 - PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
ecogelcronos@aimplas.es

This project has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° [609203].

The sole responsibility for the content of this website lies with the authors. It does not necessarily reflect the opinion of the EC. The EC is not responsible for any use that may be made of the information contained therein.